Banque Cantonale Vaudoise Purchases Shares of 2,574 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Banque Cantonale Vaudoise acquired a new stake of 2,574 shares in Regeneron Pharmaceuticals, valued at approximately $1,633,000 during the 1st quarter.
• Regeneron Pharmaceuticals reported $8.22 earnings per share for the last quarter, missing analyst estimates, with revenue of $3.03 billion compared to a projected $3.40 billion.
• Equities analysts have a consensus rating of "Moderate Buy" for Regeneron Pharmaceuticals, with a target price averaging $837.61.

Banque Cantonale Vaudoise purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 2,574 shares of the biopharmaceutical company's stock, valued at approximately $1,633,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Capital International Investors raised its stake in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after buying an additional 1,390,534 shares in the last quarter. Geode Capital Management LLC raised its position in Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after acquiring an additional 155,369 shares during the period. Dodge & Cox raised its position in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after purchasing an additional 9,381 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after acquiring an additional 810,144 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Regeneron Pharmaceuticals by 14.8% in the 4th quarter. Northern Trust Corp now owns 1,054,829 shares of the biopharmaceutical company's stock valued at $751,386,000 after acquiring an additional 136,184 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN traded up $13.41 during midday trading on Friday, hitting $558.87. 1,656,418 shares of the company traded hands, compared to its average volume of 858,977. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $60.34 billion, a price-to-earnings ratio of 14.23, a PEG ratio of 2.05 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The business has a 50 day simple moving average of $538.05 and a two-hundred day simple moving average of $604.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the business earned $9.55 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research note on Friday. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price target on the stock. Finally, Citigroup restated a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $837.61.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.